MedTrace Logo

Open-Label Safety Study of ADS-5102 in PD Patients With LID

NCT02202551 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 223

Last updated 2020-10-06

Study results available
· View outcomes & findings →

Summary

This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).

Conditions

  • Dyskinesia
  • Levodopa Induced Dyskinesia (LID)
  • Parkinson's Disease (PD)

Interventions

DRUG

ADS-5102

Sponsors & Collaborators

  • Adamas Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials Director · Adamas Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • United States
  • Austria
  • Canada
  • France
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02202551 on ClinicalTrials.gov